Comparative economic analyses of patient safety improvement strategies in acute care: A systematic review

BMJ Quality and Safety

Volumn 21, Issue 6, 2012, Pages 448-456

  Etchells, Edward ^a,b   Koo, Marika ^b   Daneman, Nick ^a,b   McDonald, Andrew ^a,b   Baker, Michael ^a,c   Matlow, Anne ^a,d   Krahn, Murray ^a,c   Mittmann, Nicole ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORHEXIDINE; CONTRAST MEDIUM; POVIDONE IODINE; RECOMBINANT ERYTHROPOIETIN;

ANTIBIOTIC RESISTANCE; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; COMPARATIVE STUDY; CONTRAST INDUCED NEPHROPATHY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DISINFECTION; DRUG SAFETY; ECONOMIC EVALUATION; EMERGENCY CARE; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPITAL CARE; HUMAN; INTENSIVE CARE UNIT; INTRAVASCULAR CATHETER; MEDICINE; MEDLINE; META ANALYSIS; PATIENT SAFETY; PHARMACIST; POSTOPERATIVE HEMORRHAGE; RETAINED INSTRUMENT; REVIEW; RISK REDUCTION; SURGICAL SPONGE; SYSTEMATIC REVIEW; TOTAL QUALITY MANAGEMENT;

COSTS AND COST ANALYSIS; CROSS INFECTION; EMERGENCY SERVICE, HOSPITAL; HUMANS; MEDICATION ERRORS; PATIENT SAFETY;

EID: 84861826747     PISSN: 20445415     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmjqs-2011-000585     Document Type: Review

References (64)

1. Mittmann N, Evans WK, Rocchi A, et al. Addendum to CADTH's Guidelines for the Economic Evaluation of Health Technologies: Specific Guidance for Oncology Products. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2009.
2. Gabriel S, Drummond M, Maetzel A, et al. OMERACT 6 Economics working group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003;30:886-90.
3. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83.
4. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. 2nd edn. Oxford, UK: Oxford Medical Publications, 1997.
5. A Review Group of the Cochrane Collaboration. Cochrane Effective Practice and Orangization of Care Group: EPOC Resources for Review Authors. 2011. http://epoc.cochrane.org/epoc-resources-review-authors
6. Thomas EJ, Studdert DM, Burstin HR, et al. Incidence and types of adverse events and negligent care in Utah and Colorado. Med Care 2000;38:261-71.
7. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research PracticesdBudget Impact Analysis. 2011. http://www.ispor.org/workpaper/ BudgetImpactAnalysis/BIA-TF0906.asp (accessed 11 Oct 2011).
8. Patented Medicine Prices review Board. Budget Impact Analysis Guidelines: Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada. 2007. http://www.pmprb-cepmb.gc.ca/cmfiles/bia-may0738lvv-5282007-5906. pdf (accessed 11 Oct 2011).
9. Shojania KG, Duncan BW, McDonald KM, et al. Making Health Practices Safer: A Critical Analysis of Patient Safety Practices. Evidence Report/Technology Assessment No. 43. Rockville, MD: Agency for Healthcare Research and Quality, 2001. http://www.ahrq.gov/clinic/ptsafety/
10. National Surgical Quality Improvement Program. Program Specifics: Data Analysis and Reporting. 2006. http://www.acsnsqip.org/main/programspecs/program- reporting.jsp
11. World Health Organization. Patient Safety: Implementing Change. 2011. http://www.who.int/patientsafety/implementation/en/
12. Klarenbach SW, Pannu N, Tonelli MA, et al. Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease. Crit Care Med 2006;34:1044-51.
13. Bank of Canada. Daily Currency Converter. 2011. http://www.bankofcanada. ca/rates/exchange/daily-converter/
14. United States Department of Labor BoLS. CPI Inflation Calculator. 2011. http://www.bls.gov/data/inflation-calculator.htm
15. Haines T, Kuys SS, Morrison G, et al. Cost-effectivness analysis of screening for risk of in-hospital falls using physiotherapist clinical judgement. Med Care 2009;47:448-56.
16. Spetz J, Jacobs J, Hatler C. Cost effectiveness of a medical vigilance system to reduce patient falls. Nurs Econ 2007;25:333-52.
17. De Giorgi I, Fonzo-Christe C, Cingria L, et al. Risk and pharmacoeconomic analyses of the injectable medication process in the paediatric and neonatal intensive care units. Int J Qual Health Care 2010;22:170-8.
18. Plowman R, Graves N, Esquivel J, et al. An economic model to assess the cost and benefits of the routine use of silver alloy coated urinary catheters to reduce the risk of urinary tract infections in catheterized patients. J Hosp Infect 2001;48:33-42.
19. Marchetti A, Jacobs J, Young M, et al. Costs and benefits of an earlyalert surveillance system for hospital inpatients. Curr Med Res Opin 2007;23:9-16.
20. Amin AN, Lin J, Johnson BH, et al. Clinical and economic outcomes with appropriate or partial prophylaxis. Thromb Res 2010;125:513-17.
21. Chiasson TC, Manns BJ, Stelfox HT. An economic evaluation of venous thromboembolism prophylaxis strategies in critically ill trauma patients at risk of bleeding. PLoS Med 2009;6:e1000098.
22. Unruh L, Agrawal M, Hassmiller S. The business case for transforming care at the bedside among the "TCAB 10" and lessons learned. Nurs Admin Q 2011;35:97-109.
23. Bradley CT, Brasel KJ, Miller JJ, et al. Cost-effectivness of prolonged thromboprophylaxis after cancer surgery. Ann Surg Oncol 2010;17:31-9.
24. Cox CE, Carson SS, Biddle AK. Cost-effectiveness of ultrasound in preventing femoral venous catheter-associated pulmonary embolism. Am J Respir Crit Care Med 2003;168:1481-7.
25. Nicolaides A, Goldhaber SZ, Maxwell GL, et al. Cost benefit of intermittent pneumatic compression for venous thromboembolism prophylaxis in general surgery. Int Angiol 2008;27:500-6.
26. Hubben G, Bootsma M, Luteijin M, et al. Modelling the costs and effects of selective and universal hospital admission screening for methicillin- resistant Staphylococcus aureus. PLoS One 2011;6: e14783.
27. Lee BY, Wettstein ZS, McGlone SM, et al. Economic value of norovirus outbreak control measures in healthcare settings. Clin Microbiol Infect 2011;17:640-6.
28. Padula WV, Mishra MK, Makic MB, et al. Improving the quality of pressure ulcer care with prevention a cost-effectiveness analysis. Med Care 2011;49:385-92.
29. Echols J, Friedman BC, Mullins RF, et al. Clinical utility and economic impact of introducing a bowel management system. J Wound Ostomy Continence Nurs 2007;34:664-70.
30. Ferrando A, Pagano E, Scaglione L, et al. A decision-tree model to estimate the impact on cost-effectivness of a venous thromboembolism prophylaxis guideline. Qual Saf Health Care 2009;18:309-13.
31. Dossett LA, Dittus RS, Speroff T, et al. Cost-effectiveness of routine radiographs after emergent open cavity operations. Surgery 2008;144:317-21.
32. Speroni KG, Lucas J, Dugan L, et al. Comparative effectiveness of standard endotracheal tubes vs. endotracheal tubes with continuous subglottic suctioning on ventilator-associated pneumonia rates. Nurs Econ 2011;29:15-20.
33. Lecumberri R, Panizo E, Gomez-Guiu A, et al. Economic impact of an electronic alert system to prevent venous thromboembolism in hospitalised patients. J Thromb Haemost 2011;9:1108-15.
34. Aspelin P, Aubry P, Fransoon SG, et al. Cost-effectiveness of iodixanol in patients at highrisk of contrast-induced nephropathy. Am Heart J 2005;149:298-303.
35. Karnon J, Campbell F, Czoski-Murray C. Model-based cost-effectivness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation). J Eval Clin Pract 2009;15:299-306.
36. Shermock KM, Horn E, Lipsett PA, et al. Number needed to treat and cost of recombinant human erythropoeitin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med 2005;33:497-503.
37. Regenbogen SE, Greenberg CC, Resch SC, et al. Prevention of retained surgical sponges: a decision-analytic model predicting relative cost-effectiveness. Surgery 2009;145: 527-35.
38. Maenthaisong R, Chaiyakunapruk N, Thamlikitkul V. Cost-effectiveness analysis of chlorhexidine gluconate compared with povidone-iodine solution for catheter-site care in Siriraj hospital, Thailand. J Med Assoc Thai 2006;89(Suppl 5): S94-101.
39. Waters HR, Korn R Jr, Colantuoni E, et al. The business case for quality: economic analysis of the Michican Keyston patient safety program in ICUs. Am J Med Qual 2011;26:333-9.
40. Kwan Y, Fernandes OA, Nagge JJ, et al. Pharmacist Medication Assessments in a Surgical Preadmission Clinic. Arch Intern Med 2007;167(10):1034-40.
41. Mcfazdean E, Isles C, Moffar J, et al. Is there a role for a prescribing pharmacist in preventing prescribing errors in the medical admissions ward? J Pharm 2003;270:896-9.
42. Scarsi KK, Fotis MA, Noskin GA. Pharmacist participation in medical rounds reduces medication errors. Am J Health-Syst Pharm 2002;59:2089-92.
43. Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993;8:289-94.
44. Collins DJ, Nickless GD, Green CF. Medication histories: does anyone know what medicines a patients should be taking? Int J Pharm Pract 2004;12:173-8.
45. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of reconbinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002;288:2827-35.
46. Chaiyakunapruk N, Veenstra DL, Lipsky BA, et al. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med 2002;136:792-801.
47. Chaiyakunapruk N, Veenstra DL, Lipsky BA, et al. Vascular catheter site care: the clinical and economic benefits of chlorhexidine gluconate compared with povidone iodine. Clin Infect Dis 2003;37:764-71.
48. Pronovost P, Needleman D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006;355:2725-32.
49. Greenberg CC, Diaz-Flores R, Lipsitz SR, et al. Bar-coding surgical sponges to improve safety: a randomized control trial. Ann Surg 2008;247:612-16.
50. Cima RR, Kollengode A, Garnatz J, et al. Incidence and characteristics of potential and actual retained foreign object events in surgical patients. J Am Coll Surg 2008;207:80-7.
51. Revesz G, Siddiqi TS, Buchheit WA, et al. Detection of retained surgical sponges. Radiology 1983;149:411-13.
52. Schmidek JM, Weeks WB. What do we know about financial returns on investments in patient safety? A literature review. Jt Comm J Qual Patient Saf 2005;31:690-9.
53. Fukuda H, Imanaka Y. Assessment of transparency of cost estimates in economic evaluations of patient safety programmes. J Eval Clin Pract 2009;15:451-9.
54. Halton K, Graves N. Economic evaluation and catheter-related bloodstream infections. Emerg Infect Dis 2007;13:815-23.
55. Chan PS, Jain R, Nallmothu BK, et al. Rapid response teams a systematic review and meta-analysis. Arch Intern Med 2010;170(1):18-26.
56. Rothschild JM, Keohane CA, Cook EF, et al. A controlled trial of smart infusion pumps to improve medication safety in critically ill patients. Crit Care Med 2005;33:533-40.
57. National Institute for Clinical Excellence. Venous Thromboembolism: Reducing the Risk. Costing Report. Implementing NICE Guidance. NICE Clinical Guideline 92. Revised 2010. 2010. http://guidance.nice.org.uk/CG92/ CostingReport/pdf/English
58. Cimiotti JP, Stone PW, Larson EL. A cost comparison of hand hygiene regimens. Nurs Econ 2004;22:196-204.
59. Conterno LO, Shymanski J, Ramotar K, et al. Real-time polymerase chain reaction detection of methicillin-resistant Staphylococcus aureus: impact on nosocomial transmission and costs. Infect Control Hosp Epidemiol 2007;28:1134-41.
60. Cummings KL, Anderson DJ, Kaye KS. Hand hygiene noncompliance and the cost of hospital-acquired methicillin-resistant Staphylococcus aureus infection. Infect Control Hosp Epidemiol 2010;31:357-64.
61. Karnon J, McIntosh A, Dean J, et al. Modelling the expected net benefits of interventions to reduce the burden of medication errors. J Health Serv Res Policy 2008;13:85-91.
62. Wu RC, Laporte A, Ungar WJ. Cost-effectiveness of an electronic medication ordering and administration system in reduing adverse drug events. J Eval Clin Pract 2007;13:440-8.
63. Zhan C, Friedman B, Mosso A, et al. Medicare payment for selected adverse events: building the business case for investing in patient safety. Health Aff (Millwood) 2006;25:1386-93.
64. Mello MM, Studdert DM, Thomas EJ, et al. Who pays for medical errors? An analysis of adverse events costs, the medical liabililty system, and incentives for patient safety improvement. J Empirical Leg Stud 2011;4:835-60.